| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | DAWN | Common Stock | Purchase | $10,000,049 | +979,667 | +8.6% | $10.21 | 12,433,535 | 18 Oct 2023 | Direct | F1, F2 |
| transaction | DAWN | Common Stock | Purchase | $3,867,372 | +384,400 | +3.1% | $10.06 | 12,817,935 | 19 Oct 2023 | Direct | F2, F3 |
| transaction | DAWN | Common Stock | Purchase | $1,110,907 | +111,387 | +0.87% | $9.97 | 12,929,322 | 20 Oct 2023 | Direct | F2, F4 |
| Id | Content |
|---|---|
| F1 | The price reported in Column 4 is a weighted average purchase price of the shares of common stock. The shares of common stock were purchased in multiple transactions ranging from $10.07 to $10.29 inclusive. The reporting persons undertake to provide to Day One Biopharmaceuticals, Inc., any security holder of Day One Biopharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares of common stock purchased at each separate price within the ranges set forth in this footnote to this Form 4. |
| F2 | The securities reported are held directly by AI Day1 LLC and may be deemed to be beneficially owned by Access Industries Holdings LLC ("AIH"), Access Industries Management, LLC ("AIM") and Len Blavatnik because AIH indirectly controls all of the outstanding voting interests in AI Day1 LLC, AIM controls AIH and Mr. Blavatnik controls AIM and controls a majority of the outstanding voting interests in AIH. AIH, AIM and Mr. Blavatnik each disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, and this form shall not be construed as an admission that any such reporting person is the beneficial owner of any of the securities reported on this form. |
| F3 | The price reported in Column 4 is a weighted average purchase price of the shares of common stock. The shares of common stock were purchased in multiple transactions ranging from $9.88 to $10.20 inclusive. The reporting persons undertake to provide to Day One Biopharmaceuticals, Inc., any security holder of Day One Biopharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares of common stock purchased at each separate price within the ranges set forth in this footnote to this Form 4. |
| F4 | The price reported in Column 4 is a weighted average purchase price of the shares of common stock. The shares of common stock were purchased in multiple transactions ranging from $9.83 to $10.13 inclusive. The reporting persons undertake to provide to Day One Biopharmaceuticals, Inc., any security holder of Day One Biopharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares of common stock purchased at each separate price within the ranges set forth in this footnote to this Form 4. |